이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Pediatrix Medical Group 관리

관리 기준 확인 2/4

Pediatrix Medical Group's CEO는 Jim Swift, Jan2023 에 임명되었습니다 의 임기는 1.58 년입니다. 총 연간 보상은 $ 2.24M, 29% 로 구성됩니다. 29% 급여 및 71% 보너스(회사 주식 및 옵션 포함). 는 € 1.75M 가치에 해당하는 회사 주식의 0.21% 직접 소유합니다. 1.75M. 경영진과 이사회의 평균 재임 기간은 각각 2.6 년과 4.1 년입니다.

주요 정보

Jim Swift

최고 경영자

US$2.2m

총 보상

CEO 급여 비율	29.0%
CEO 임기	1.7yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	2.7yrs
이사회 평균 재임 기간	4.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jim Swift 의 보수는 Pediatrix Medical Group 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$252m
Mar 31 2024	n/a	n/a	-US$71m
Dec 31 2023	US$2m	US$650k	-US$60m
Sep 30 2023	n/a	n/a	US$88m
Jun 30 2023	n/a	n/a	US$95m
Mar 31 2023	n/a	n/a	US$98m
Dec 31 2022	US$1m	US$450k	US$63m

보상 대 시장: Jim 의 총 보상 ($USD 2.24M )은 German 시장( $USD 1.46M ).

보상과 수익: 회사가 수익성이 없는 동안 Jim 의 보상이 증가했습니다.

CEO

Jim Swift (62 yo)

1.7yrs

테뉴어

US$2,237,839

보상

Dr. James D. Swift, M.D., also known as Jim, is Director of Brave Care, Inc. since October 2021. He had been the Chief Operating Officer at Pediatrix Medical Group, Inc. since May 2022 until December 31, 2...

리더십 팀

이름	위치	테뉴어	보상	소유권
James Swift	CEO & Director	1.7yrs	US$2.24m	0.20% $ 1.7m
C. Richards	Executive VP & CFO	4yrs	US$1.78m	0.21% $ 1.8m
Mary Ann Moore	Executive VP	1.9yrs	US$1.83m	0.19% $ 1.6m
John Pepia	Senior VP & Chief Accounting Officer	8.3yrs	US$1.43m	데이터 없음
Cheryl VanPatten	Senior VP & Chief Information Officer	2.7yrs	데이터 없음	데이터 없음
Daniel Corcoran	Senior Vice President of Administration & Managed Care	no data	데이터 없음	데이터 없음
Charles Lynch	Senior VP of Finance	no data	데이터 없음	데이터 없음
Meghan Lublin	Senior VP	3.1yrs	데이터 없음	데이터 없음
Mike Ashford	President of Regional Operations (Central)	no data	데이터 없음	데이터 없음
Michael Dwyer	President of Regional Operations (South-Central)	no data	데이터 없음	데이터 없음
Nanette Sanders	Senior Vice President of Operations	no data	데이터 없음	데이터 없음
Linda Chen	President of Regional Operations (West)	2.4yrs	데이터 없음	데이터 없음

2.7yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 관리: PDC 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
James Swift	CEO & Director	1.5yrs	US$2.24m	0.20% $ 1.7m
Mark Ordan	Chair	4.2yrs	US$554.45k	0.20% $ 1.7m
Guy Sansone	Lead Independent Director	4.2yrs	US$295.00k	0.081% $ 688.9k
Thomas McEachin	Independent Director	4.2yrs	US$252.50k	0.065% $ 551.0k
Sylvia Young	Independent Director	1.3yrs	US$201.00k	0.035% $ 294.4k
John Starcher	Independent Director	4.2yrs	US$230.00k	0.065% $ 551.0k
Shirley Weis	Independent Director	4.2yrs	US$245.00k	0.043% $ 363.3k
Gavin Molinelli	Board Observer	4.2yrs	데이터 없음	데이터 없음
Michael Rucker	Independent Director	5.3yrs	US$242.50k	0.069% $ 586.4k
Laura Linynsky	Independent Director	2.3yrs	US$230.00k	0.023% $ 196.1k

4.2yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: PDC 의 이사회는 경험(평균 재직 기간 4.1 년)으로 간주됩니다.

Pediatrix Medical Group 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Executive VP & CFO recently sold €461k worth of stock

Pediatrix Medical Group, Inc., Annual General Meeting, May 09, 2024

CEO & Director recently sold €172k worth of stock

Independent Director recently sold €238k worth of stock

Pediatrix Medical Group, Inc. Appoints Sylvia Young as an Independent Director, Effective May 12, 2023

Pediatrix Medical Group, Inc. Announces Executive Changes

Recent updates

Executive VP & CFO recently sold €461k worth of stock

New minor risk - Shareholder dilution

New minor risk - Share price stability

Pediatrix Medical Group, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: EPS: US$0.048 (vs US$0.17 in 1Q 2023)

Pediatrix Medical Group, Inc. to Report Q1, 2024 Results on May 07, 2024

Pediatrix Medical Group, Inc., Annual General Meeting, May 09, 2024

Full year 2023 earnings released: US$0.73 loss per share (vs US$0.75 profit in FY 2022)

Pediatrix Medical Group, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Investor sentiment deteriorates as stock falls 17%

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: EPS: US$0.26 (vs US$0.35 in 3Q 2022)

Pediatrix Medical Group, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.36 in 2Q 2022)

CEO & Director recently sold €172k worth of stock

Independent Director recently sold €238k worth of stock

Pediatrix Medical Group, Inc. Appoints Sylvia Young as an Independent Director, Effective May 12, 2023

First quarter 2023 earnings released: EPS: US$0.17 (vs US$0.24 loss in 1Q 2022)

Full year 2022 earnings released: EPS: US$750 (vs US$1.27 in FY 2021)

Pediatrix Medical Group, Inc. Announces Executive Changes

CEO & Director recently sold €334k worth of stock

High number of new and inexperienced directors

Executive VP & Chief Operating Officer recently sold €368k worth of stock

Third quarter 2022 earnings released: EPS: US$0.35 (vs US$0.37 in 3Q 2021)

Pediatrix Medical Group, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Pediatrix Medical Group, Inc. Announces Executive Changes

Second quarter 2022 earnings released: EPS: US$0.36 (vs US$0.36 in 2Q 2021)

Pediatrix Medical Group, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Mednax Announces Leadership Appointments

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.063 profit in 1Q 2021)

High number of new directors

MEDNAX, Inc. to Report Q1, 2022 Results on Apr 28, 2022

MEDNAX, Inc., Annual General Meeting, May 12, 2022

MEDNAX, Inc. Announces Resignation of Roger Mack Hinson as President of Pediatrix and Obstetrix Medical Group, Effective as of June 1, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

MEDNAX, Inc. Provides Earnings Guidance for the Year 2022

MEDNAX, Inc. to Report Q4, 2021 Results on Feb 17, 2022

MEDNAX, Inc. (NYSE:MD) acquired Night Lite Pediatrics.

Senior VP & Chief Accounting Officer recently sold €215k worth of stock

Third quarter 2021 earnings released: EPS US$0.37 (vs US$0.032 loss in 3Q 2020)

Senior VP & Chief Accounting Officer recently sold €268k worth of stock

Second quarter 2021 earnings released: EPS US$0.36 (vs US$0.085 in 2Q 2020)

New 90-day high: €23.60

Full year 2020 earnings released: US$0.12 loss per share (vs US$13.77 loss in FY 2019)

Revenue misses expectations

MEDNAX, Inc. to Report Q4, 2020 Results on Feb 18, 2021

New 90-day high: €20.00

Federman & Sherwood Files First Data Breach Case Against MedNax, Inc. and Pediatrix Medical Group

New 90-day high: €19.60

New 90-day high: €17.20

New 90-day high: €16.60

Revenue misses expectations

Third quarter 2020 earnings released: US$0.032 loss per share

New 90-day low: €12.80

New 90-day low: €14.10

Executive VP recently sold €352k worth of stock

New 90-day high - €17.30

MEDNAX, Inc. to Report Q2, 2020 Results on Jul 30, 2020

MEDNAX, Inc. Announces Executive Change

MEDNAX, Inc.(NYSE:MD) dropped from Russell 1000 Dynamic Index

MEDNAX, Inc.(NYSE:MD) dropped from Russell 1000 Index

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원